NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$4.70
-0.15 (-3.09 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.66
$4.89
50-Day Range
$3.71
$5.13
52-Week Range
$3.66
$15.24
Volume4.27 million shs
Average Volume4.44 million shs
Market Capitalization$439.51 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63
30 days | 90 days | 365 days | Advanced Chart
Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.


Athenex logo

About Athenex

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

465th out of 2,097 stocks

Pharmaceutical Preparations Industry

229th out of 831 stocks

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Athenex (NASDAQ:ATNX) Frequently Asked Questions

Is Athenex a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athenex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View analyst ratings for Athenex
or view top-rated stocks.

What stocks does MarketBeat like better than Athenex?

Wall Street analysts have given Athenex a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athenex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) posted its earnings results on Wednesday, May, 5th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.13. Athenex had a negative net margin of 110.02% and a negative trailing twelve-month return on equity of 89.73%.
View Athenex's earnings history
.

How has Athenex's stock price been impacted by COVID-19 (Coronavirus)?

Athenex's stock was trading at $9.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATNX shares have decreased by 51.3% and is now trading at $4.70.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ATNX?

9 brokers have issued twelve-month price objectives for Athenex's shares. Their forecasts range from $5.00 to $33.00. On average, they anticipate Athenex's stock price to reach $13.86 in the next twelve months. This suggests a possible upside of 194.8% from the stock's current price.
View analysts' price targets for Athenex
or view top-rated stocks among Wall Street analysts.

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 61, Pay $480.75k)
  • Mr. Randoll Sze, Chief Financial Officer (Age 40, Pay $372.89k)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 72, Pay $693.45k)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Chief Medical Officer (Age 68, Pay $483.2k)
  • Dr. Simon C. Pedder Ph.D., Chief Bus. & Strategy Officer of Proprietary Products (Age 60, Pay $392.42k)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus
  • Ms. Teresa Brophy Bair, Gen. Counsel, Sr. VP of Admin. & Corp. Sec. (Age 50)
  • Mr. Steven Rubis, Sr. Director of Investor Relations
  • Ms. Jacqueline Li, Director of Corp. Devel. & Investor Relations
  • Mr. Daniel Lang M.D., Sr. Director of Corp. Devel.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.68%), Geode Capital Management LLC (1.33%), Millennium Management LLC (1.09%), Northern Trust Corp (0.82%), Citigroup Inc. (0.79%) and UBS Group AG (0.78%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, Stephanie A Davis and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Schonfeld Strategic Advisors LLC, Victory Capital Management Inc., Deltec Asset Management LLC, Royal Bank of Canada, Northern Trust Corp, JPMorgan Chase & Co., and Jaffetilchin Investment Partners LLC.
View insider buying and selling activity for Athenex
or view top insider-selling stocks.

Which major investors are buying Athenex stock?

ATNX stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, Rafferty Asset Management LLC, First Midwest Bank Trust Division, Credit Suisse AG, Hennion & Walsh Asset Management Inc., Occudo Quantitative Strategies LP, and Millennium Management LLC. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan, and Stephanie A Davis.
View insider buying and selling activity for Athenex
or or view top insider-buying stocks.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $4.70.

How much money does Athenex make?

Athenex has a market capitalization of $439.51 million and generates $144.39 million in revenue each year. The company earns $-146,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Athenex have?

Athenex employs 593 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

Where are Athenex's headquarters?

Athenex is headquartered at 1001 Main Street Suite 600, Buffalo NY, 14203.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.